Australia's CSL gains on US tariff relief on key product imports

Csl

07/04/2026 03:40

** Shares of Australia's CSL Ltd CSL.AX rise as much as 2.8% to A$142.78, their biggest intraday pct gain since March 20, 2026

** Australian biotech giant responds to U.S. administration's announcement on 2 April, intending to impose tariffs on pharmaceutical products imported to the U.S.

** "Initial view is that most of CSL's U.S. product sales will not be subject to tariffs", says co

** Says administration has recognised 'unique nature' of plasma-derived therapies under proclamation

** Says unit CSL Seqirus' primary product sold in U.S. is Fluad, manufactured in UK, where tariff rate is presently 10%. Co expects this tariff will reduce to 0%

** Stock down 18.5% YTD

 (Reporting by Aamir Sheik Khalid in Bengaluru)

 ((Aamir.SheikKhalid@thomsonreuters.com))